The head of US drug maker Pfizer said today that his company would not submit a COVID-19 vaccine for approval or emergency use authorization (EUA) if its scientists don't have data from large phase 3 trials showing safety and efficacy."We will never submit for authorization or approval any vaccine before we feel that it is safe and effective," Albert Bourla, DVM, PhD, chairman and CEO of Pfizer, said in a press briefing organized by the International Federation of Pharmaceutical Manufacturers and Associations. "We will not cut corners."The comments come amid growing concerns that the Food and Drug Administration (FDA) could issue an EUA for a vaccine prior to the Nov 3 presidential election without enough data from phase 3 trials.